InvestorsHub Logo
Followers 59
Posts 3755
Boards Moderated 0
Alias Born 05/25/2021

Re: None

Monday, 05/13/2024 7:22:55 PM

Monday, May 13, 2024 7:22:55 PM

Post# of 696728
BMS filed FDA approval for subcutaneous nivolumab and PUDFA is on February 28, 2025. Don't recall Merck has released its Top-line data on its SC keytruda.

U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)

https://news.bms.com/news/corporate-financial/2024/U.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-Application-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase/default.aspx
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News